Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CATIP antisense RNA 1 (CATIP-AS1)
- Target
- CATIP-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA
01
Overview
CATIP antisense RNA 1 (CATIP-AS1) is a long non-coding RNA (lncRNA) transcribed from the antisense strand of the CATIP gene locus. Recent studies have implicated CATIP-AS1 as a tumor suppressor in thyroid cancer, where it is significantly downregulated compared to normal tissue. Low levels of CATIP-AS1 are associated with poor prognosis in thyroid cancer patients. Functionally, overexpression of CATIP-AS1 inhibits thyroid cancer cell proliferation, migration, and EMT, while promoting apoptosis. Mechanistically, CATIP-AS1 acts as a molecular sponge for miR-515-5p, antagonizing its effects and leading to upregulation of SMAD4, a critical mediator of the TGF-β pathway important in cancer biology. These findings suggest that CATIP-AS1 may serve as a novel biomarker for thyroid cancer detection and prognosis, and may be explored as a potential therapeutic target in the future[2][3][4][5].
- Other names
- CATIP-AS1
02
Biological functions
Regulation of gene expression, particularly acting as a competing endogenous RNA (ceRNA) by sponging specific microRNAs (e.g., miR-515-5p)Modulation of epithelial–mesenchymal transition (EMT)Influencing cell proliferation, apoptosis, and migration in thyroid cancer cells
03
Disease associations
Cancer (especially thyroid cancer/THCA)Potentially implicated in other cancers or diseases where lncRNA dysfunction is involved, though most data is specific to thyroid cancer at this time
04
Biomarkers
Biomarker for poor prognosis in thyroid cancer—lower CATIP-AS1 expression is associated with worse outcomesPotential early detection marker for thyroid cancer
Beyond the preview
Go deeper on CATIP antisense RNA 1 (CATIP-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CATIP antisense RNA 1 (CATIP-AS1).